Findings

What do systematic reviews say?

52 questions · 52 findings · 6 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 3.8%GRADE not reported 0 · 0%Very low 14 · 26.9%Low 24 · 46.2%Moderate 10 · 19.2%High 2 · 3.8%

Behavioural activation vs no treatment

quality of life (continuous)up to 6 months (2 weeks) · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
High

Behavioural activation vs no treatment

Anxiety · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Low

Behavioural activation vs treatment

depression symptoms (continuous) up to 6 months (4‐8 weeks) · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 2208 participants
Low

Behavioural activation vs treatment

quality of life (continuous)up to 6 months (2 weeks) · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1299 participants
Very low

Behavioural activation vs treatment

social adjustment and functioning (continuous)up to 6 months (12 weeks) · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 88 participants
Low

Behavioural activation vs treatment

Anxiety · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1063 participants
Moderate

Behavioural activation vs CBT

social adjustment and functioning (continuous)up to 6 months (12 weeks) · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 111 participants
Very low

Behavioural activation vs CBT

Anxiety · depression in adults

1 finding from 1 review

Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 646 participants
Moderate

Antidepressants plus benzodiazepines vs antidepressants alone

Depression severity: continuous phase (> 12 weeks) · patients with major depression

1 finding from 1 review

Antidepressants plus benzodiazepines for adults with major depression 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
Low

Lithium vs lamotrigine

Efficacy: response (continuous) change in BPRS (total) from baseline to end of study ‐all data · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 301 participants
Moderate

Lithium vs placebo

Efficacy: response (continuous) Change in YMRS (ITT‐LOCF) from baseline to end of study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 935 participants
High

Lithium vs carbamazepine

Efficacy: response (continuous) YMRS/BPRS change from baseline to end of study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 102 participants
Very low

Lithium vs carbamazepine

Efficacy: response (continuous) CGI change from baseline to end of study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 76 participants
Moderate

Lithium vs QUETIAPINE

Efficacy: response (continuous) Change in YMRS (ITT‐LOCF) from baseline to end of study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 359 participants
Low

Lithium vs OLANZAPINE

Efficacy: response (continuous) CGI severity score at end of study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 210 participants
Low

Lithium vs chlorpromazine

Efficacy: response (continuous) change in BPRS (total) from baseline to end of study ‐all data · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 284 participants
Very low

Lithium vs haloperidol

Efficacy: response (continuous) change in BPRS (total) from baseline to end of study ‐all data · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 80 participants
Very low

Lithium vs Zuclopenthixol (Cis Z/Trans E isomer)

Efficacy: response (continuous) change in BPRS (total) from baseline to end of study ‐all data · acute mania

The review found no eligible studies for this question.

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lithium vs RISPERIDONE

Efficacy: response (continuous) YMRS/MRS change at the end of the study · acute mania

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 241 participants
Low

Lithium vs ARIPIPRAZOLE

Efficacy: response (continuous) YMRS change by ≥ 50% at end of study · acute mania

Lithium showed no clear difference in efficacy: response (continuous) YMRS change by ≥ 50% at end of study compared with aripiprazole (moderate certainty).

1 finding from 1 review

Lithium for acute mania 2019 · Cochrane Headline outcomes only
OR 0.96 [0.62, 1.51]
1 study · 309 participants
Moderate